Click here to view the programme of Session 2b

Chairs:
Peter van Rossum, radiation-oncologist, Amsterdam UMC, The Netherlands
Marianne Nordsmark, Aarhus University Hospital, Aarhus, Denmark
Jiafu Ji, surgeon, First Affiliated Hospital of Nanjing Medical University, China

15:30 CRITICS trials
Marcel Verheij, radiation-oncologist, Radboud University, Nijmegen, The Netherlands

15:50 TOPGEAR trial
Trevor Leong, radiation-oncologist, Peter MacCallum Cancer Centre, Melbourne, Australia

16:10 ARTIST trials
Dohoon Lim, radiation-oncologist, Samsung Medical Center, Seoul, Korea

16:30 Accepted oral abstract 01.1.13: Neoadjuvant Serplulimab with Concurrent Chemoradiotherapy in Resectable Esophagogastric Junction Adenocarcinoma: Phase 2 Updated Results
Lin Zhao, Medical oncologist, Pekingumch, China

16.40 Accepted oral abstract 01.1.14: The value of chemoradiation therapy for resectable esophago-gastric adenocarcinomas: A meta-analysis of randomized clinical trials
Tao Fu, Surgeon, China – Japan Friendship Hospital, China

16:50 Accepted oral abstract 01.1.15: Radiotherapy for ANTIhemorrhagic purpose in GAastric cancer: the RANTIGA Trial.
Valeria Epifani, Resident, Radiation Oncology Section, Department of Medicine and Surgery, University of Perugia, Perugia, Italy

17:00 End of session